Beijing Hotgen Biotech Co., Ltd. (SHA:688068)
61.66
-2.77 (-4.30%)
Nov 17, 2026, 3:00 PM CST
Beijing Hotgen Biotech Revenue
Beijing Hotgen Biotech had revenue of 107.22M CNY in the quarter ending September 30, 2026, with 3.02% growth. This brings the company's total for the last twelve months to 472.32M, up 9.55% year-over-year. In the year 2025, Beijing Hotgen Biotech had annual revenue of 404.88M, down -20.58%. That makes Beijing Hotgen Biotech the 25,379th largest company in the world by revenue and 4,519th in China.
Revenue (ttm)
472.32M
Revenue Growth
+9.55%
P/S Ratio
11.51
Revenue / Employee
452.84K
Employees
1,043
Market Cap
5.44B
Revenue by Geography
- China 373.50M 94.4%
- Overseas 21.96M 5.6%
Fiscal year ended Dec 31, 2025 See the full Beijing Hotgen Biotech breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 404.88M | -104.90M | -20.58% |
| Dec 31, 2024 | 509.78M | -38.06M | -6.95% |
| Dec 31, 2023 | 547.84M | -3.01B | -84.60% |
| Dec 31, 2022 | 3.56B | -1.81B | -33.76% |
| Dec 31, 2021 | 5.37B | 4.86B | 945.54% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Youcare Pharmaceutical Group | 2.36B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.43B |
| Chengdu Kanghua Biological Products | 1.21B |
| R&G PharmaStudies | 957.42M |
| Wuhan Keqian Biology Co.,Ltd | 786.77M |
| Zhejiang Ausun Pharmaceutical | 757.05M |
| PharmaResources (Shanghai) | 724.75M |
| Jiangsu Aidea Pharmaceutical Group | 716.78M |